Precisis, a Heidelberg medtech company led by CEO Karl Stoklosa, makes EASEE, a neurostimulator for drug-resistant focal epilepsy whose electrodes sit under the scalp and above the skull without touching the brain. CORDIS describes it as "the first minimally invasive device for focal cortical stimulation", combining high-frequency bursts meant to stop seizures with a daily 20-minute DC-like session meant to calm the overexcitable brain area, according to CORDIS.
The European Innovation Council granted €2,495,836 towards a €3.57 million project, BFORE, from March 2023 to February 2025, to take clinical prototypes at TRL 6-7 to a series product at TRL 9. The final report says the implant was redesigned for reliability, safety, lifetime and lower power use, manufacturing moved from manual prototype steps to "better controlled, scalable and partly automated" production, and an end-of-line test system for the series device was developed. In 2025 the European Investment Bank lent Precisis €20 million and said more than 150 patients had been implanted.
Company file
- Legal entity
- PRECISIS GmbH, HRB 741686, Mannheim court, Heidelberg
- Founder
- Angela Liedler
- Managing directors
- Karl Stoklosa (CEO), Michael Tittelbach (CTO)
- Product
- EASEE, CE-marked 2022
- Markets
- Germany, Austria, Switzerland, UK, Portugal, Italy
- Shareholder named
- URSAPHARM Arzneimittel GmbH
- EIC project
- BFORE, 1 Mar 2023 to 28 Feb 2025, closed
- EIC funding
- Grant first
Where Precisis Stands Now
In November 2025 the US Food and Drug Administration approved an investigational device exemption for EASEE4US, a pivotal study in about 200 patients, and the company said it was still seeking investors to complete its Series B. In September 2026 the EIB named Precisis an Innovation Champion at its TechEU Equity Summit. It filed its 2024 accounts in June 2026 and kept filing patents, including one on training an algorithm to detect neurological conditions, according to North Data.
"With the first wave of funding secured, we are now actively engaging with investors to complete our series B round and accelerate our expansion first to other European countries and then the U.S. market."
Karl Stoklosa, CEO, Precisis, October 2025The Technology: Stimulation From Above the Skull
Deep brain stimulation and vagus nerve stimulation carry higher risk, the EIB says. EASEE places a Laplace-type electrode, a central contact surrounded by four independently driven electrodes, over the seizure focus under the scalp, avoiding a craniotomy. The EIB cites a 2025 study in Epilepsia reporting that 65% of patients halved their seizures and 81% stayed on therapy after two years.
What the EIC Project Promised, and What CORDIS Shows
The project had four goals: securing the business case and patents, expanding commercialisation, improving safety and reliability, and scaling from prototype to series production. The report documents a granted European unitary patent on the electrode design, reimbursement secured in several European countries, a redesign aligned with the medical device regulation including cybersecurity work, and a scalable production process with an end-of-line tester. It does not give unit volumes or sales. CORDIS lists the project as closed.
- Series-ready redesignDeliveredMDR-aligned, per report.
- Scalable productionDeliveredPartly automated, tester built.
- Reimbursement and marketsDeliveredSix countries.
- Sales volumesUnverifiedNot published.
The Money
Besides the EIC grant, Precisis received €1.54 million in German federal grants for a trial in young patients, €718,419 for an edge-electronics project and €1 million in Baden-Württemberg state aid, North Data lists. The EIB loan is backed by the EU's InvestEU programme. Precisis's 2024 accounts are filed but not publicly summarised with revenue, and the €37 million Series B has not been announced as closed.
What Cannot Be Checked
Questions for the EIC
How many EASEE systems Precisis sells a year, what its revenue and losses are, and whether its Series B closed are not public. Nor is how the EIC measured the move to TRL 9.
Why Europe Should Care
About 30% of people with epilepsy do not respond to medication alone, Precisis says. EASEE is a European-made therapy between drugs and brain surgery that is already reimbursed in several countries. EU money, through the EIC grant and the EIB loan, has carried it from prototype towards the US market; private equity at the size the company seeks has not yet been announced.
What the project promised
A series product at TRL 9, scalable manufacturing and wider market access for EASEE.
What the record shows
A redesigned implant, scaled production, six markets, 150+ patients, an EIB loan and an FDA-approved pivotal trial.
The Verdict
Delivered, commercial scale unproven
Precisis did what the EIC paid for and its implant is in clinical use. Whether it becomes a large business depends on a US trial and an equity round it has not yet closed.
Precisis and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
